Sanofi adds BTK inhibitors to pipeline with $3.68bn Principia Biopharma acquisition
pharmaphorum
AUGUST 17, 2020
Sanofi’s acquisition builds on a partnership to develop central nervous system drugs that began in late 2017. In a statement Sanofi said that the acquisition will give it full control of the brain-penetrant BTK inhibitor, SAR442168, making marketing more efficient and eliminating any royalty payments due under the 2017 agreement.
Let's personalize your content